Medtide

Medtide Goodwill

The Goodwill of Medtide (3880.HK) as of Oct 22, 2026 is 95.41 M CNY. In the previous year, Goodwill was 95.41 M CNY — a change of 0.00% (lower).

Goodwill

95.41 MCNY

YoY

0.00%

Last updated:

Goodwill of Medtide is 2025 95.41 M CNY. Goodwill of Medtide was 2024 95.41 M CNY. It decreases by 0.00% lower compared to the previous year.

The Medtide Goodwill history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill
Date
Goodwill
Jan 1, 2021
95.41 M CNY
Jan 1, 2022
95.41 M CNY
Jan 1, 2023
95.41 M CNY
Jan 1, 2024
95.41 M CNY
Jan 1, 2025
95.41 M CNY
The Medtide Goodwill history
YEARGoodwillYoY
95.41 MCNY0.00%
95.41 MCNY0.00%
95.41 MCNY0.00%
95.41 MCNY0.00%
95.41 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medtide Stock analysis

What does Medtide do? Medtide, Inc. generates revenue through peptide-focused contract research, development, and manufacturing services. The company offers CRO services for peptide new chemical entity (NCE) discovery and synthesis, alongside CDMO services covering peptide chemistry, manufacturing, and control (CMC) development and commercial production. Its primary clients are pharmaceutical companies seeking active pharmaceutical ingredients (APIs) rather than finished drug products, with services delivered across domestic and overseas markets. The firm's revenue streams are derived from these specialized peptide-related R&D and manufacturing contracts. Medtide's business model centers on providing comprehensive peptide development and manufacturing solutions, including CMC filing support for clients. The company's services target the API segment of the pharmaceutical industry, focusing on peptide-based drug development rather than final drug formulations. This specialization allows Medtide to serve clients requiring high-quality peptide synthesis and manufacturing capabilities for their drug development pipelines. The company's revenue is generated through direct contracts with pharmaceutical firms for peptide-related services, including discovery synthesis, CMC development, and commercial manufacturing. These services are delivered to clients operating in both domestic and international markets, with the firm emphasizing its expertise in peptide chemistry and manufacturing processes. Medtide's business model relies on its ability to provide end-to-end peptide development and manufacturing solutions to pharmaceutical clients. Medtide is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medtide stock

Goodwill of Medtide is 95.41 M CNY in 2025.

Goodwill of Medtide changed from 95.41 M CNY to 95.41 M CNY, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Goodwill Medtide since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Medtide historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Medtide

All Key Metrics — Medtide